Video

Dr. Hope on Using 68Ga-PSMA-11 to Detect Pelvic Nodal Metastasis in Prostate Cancer

Author(s):

Thomas Hope, MD, discusses the rationale for using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Thomas Hope, MD, an associate professor of radiology and director of Molecular Therapy for the Molecular Imaging and Therapeutics Clinical Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco (UCSF), discusses the rationale for using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

A prospective phase 3 trial evaluated the sensitivity and specificity of the radiotracer 68Ga-PSMA-11 in detecting pelvic nodal metastases at the time of radical prostatectomy in men with intermediate- or high-risk prostate cancer.

Previously published data from Europe demonstrated the utility of Ga68-PSMA-11 in this setting, says Hope.

Positive findings from this study support the utility of this radiotracer, as well as the submission of a New Drug Application to the FDA, concludes Hope.

Related Videos
Aditya Bardia, MD, MPH, FASCO
Christina S. Baik, MD, MPH
Dana Zakalik, MD
David C. Fisher, MD
Kevin Kalinsky, MD, MS
Alberto Montero, MD, MBA, CPHQ
R. Lor Randall, MD, FACS
Daniel E. Haggstrom, MD
Jairam Krishnamurthy, MD, FACP
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System